ADT (ADT) has been quietly grinding higher this year, and with shares still trading under ten dollars, investors are wondering whether the home security leader’s improving fundamentals are fully ...

Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of the ArteraAI Prostate Test (Post?RP) for patients experiencing biochemical ...

The five-round card battle starts on Wednesday at Lake View Resort in Hua Hin, where the leading 140 players and ties after ...

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

The best home security systems on the market give customers peace of mind while protecting their home and family from ...

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

ADT Self Setup, formerly Blue by ADT, offers security system equipment that you can install yourself. You get access to the same ADT monitoring as professionally ...

Johnson Controls International Plc, a multinational company manufacturing security equipment and systems for buildings and structures, intends to sell the ADT Alarms division for $2 billion. This is ...

J. William Carpenter is an economist who writes financial topics. He is an author of published works for higher education and business clients. Doretha Clemons, Ph.D., MBA, PMP, has been a corporate ...